Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15620 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Domenica Rubino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Washington Center for Weight Management and Research, Arlington, Virginia, USA. Hauptthemen laut MEDLINE: Quality of Life, Glucagon-Like Peptides, Patient Reported Outcome Measures, Obesity. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
Aims
To summarize the effects of semaglutide 2.4 mg on weight‐related quality of life (WRQOL) and health‐related quality of life (HRQOL), focusing on the confirmatory secondary endpoint of physical functioning. Materials and Methods The STEP 1–4 Phase 3a, 68‐week, double‐blind, randomized controlled trials assessed the efficacy and safety of semaglutide 2.4 mg versus placebo in individuals with overweight/obesity. WRQOL and HRQOL were assessed by change from baseline to Week 68 in two different but complementary measures, the Impact of Weight on Quality of Life‐Lite Clinical Trials Version (IWQOL‐Lite‐CT; STEP 1 and 2) and the SF‐36v2 Health Survey Acute (SF‐36v2; STEP 1–4).
Results
Superiority for semaglutide 2.4 mg over placebo based on IWQOL‐Lite‐CT and SF‐36v2 physical functioning scores was confirmed in STEP 1 and 2 and in STEP 1, 2 and 4, respectively. At Week 68, a greater proportion of participants treated with semaglutide 2.4 mg than with placebo reached meaningful within‐person change (MWPC) thresholds for IWQOL‐Lite‐CT Physical Function scores in STEP 1 (51.8% vs. 28.3%; p < 0.0001) and STEP 2 (39.6% vs. 29.5%; p = 0.0083) and the MWPC threshold for SF‐36v2 Physical Functioning in STEP 1 (39.8% vs. 24.1%; p < 0.0001), STEP 2 (41.0% vs. 27.3%; p = 0.0005) and STEP 4 (18.0% vs. 6.6%; p < 0.0001). All other IWQOL‐Lite‐CT and SF‐36v2 scale scores in STEP 1–4 were numerically improved with semaglutide 2.4 mg versus placebo, except for SF‐36v2 Role Emotional in STEP 2.
Conclusions
Semaglutide 2.4 mg significantly improved physical functioning, with greater proportions of participants achieving MWPC compared with placebo, and showed beneficial effects on WRQOL and HRQOL beyond physical functioning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Washington Center for Weight Management and Research, Arlington, Virginia, USA.
- QualityMetric Inc., LLC, Johnston, Rhode Island, USA.
- Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
- Novo Nordisk A/S, Søborg, Denmark.
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
- York University, McMaster University and Wharton Weight Management Clinic, Toronto, Ontario, Canada.
ORCID-Profile: Domenica Rubino, Jakob B Bjorner, Arya M Sharma, Sean Wharton, Thomas Wadden, Ronette L Kolotkin
Förderung
- Novo Nordisk A/S
Zitieren
APA
Rubino, D., Bjorner, J. B., Rathor, N., Sharma, A. M., von Huth Smith, L., Wharton, S., Wadden, T., Zeuthen, N., & Kolotkin, R. L. (2024). Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15620
Vancouver
Rubino D, Bjorner JB, Rathor N, Sharma AM, von Huth Smith L, Wharton S, et al. Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15620
BibTeX
@article{Rubino2024,
author = {Rubino, Domenica and Bjorner, Jakob B and Rathor, Naveen and Sharma, Arya M and von Huth Smith, Lisa and Wharton, Sean and Wadden, Thomas and Zeuthen, Niels and Kolotkin, Ronette L},
title = {Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15620}
}
EUVIMED